Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 12/2011

01.12.2011 | Review

Molecular Mechanisms of Barrett’s Esophagus

verfasst von: Hao Chen, Yu Fang, Whitney Tevebaugh, Roy C. Orlando, Nicholas J. Shaheen, Xiaoxin Chen

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Barrett’s esophagus (BE) is defined as the metaplastic conversion of esophageal squamous epithelium to intestinalized columnar epithelium. As a premalignant lesion of esophageal adenocarcinoma (EAC), BE develops as a result of chronic gastroesophageal reflux disease (GERD). Many studies have been conducted to understand the molecular mechanisms of this disease. This review summarizes recent results involving squamous and intestinal transcription factors, signaling pathways, stromal factors, microRNAs, and other factors in the development of BE. A conceptual framework is proposed to guide future studies. We expect elucidation of the molecular mechanisms of BE to help in the development of improved management of GERD, BE, and EAC.
Literatur
1.
Siersema PD. Pathogenesis, diagnosis and therapeutic possibilities of esophageal cancer. Curr Opin Gastroenterol. 2007;23:456–461.PubMedCrossRef
2.
O’Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus: report on the Cleveland Clinic Barrett’s Esophagus Registry. Am J Gastroenterol. 1999;94:2037–2042.PubMed
3.
Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92:212–215.PubMed
4.
Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus. 2007;20:36–41.PubMedCrossRef
5.
Fennerty MB, Triadafilopoulos G. Barrett’s-related esophageal adenocarcinoma: is chemoprevention a potential option? Am J Gastroenterol. 2001;96:2302–2305.PubMedCrossRef
6.
Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677.PubMedCrossRef
7.
Spechler SJ. Barrett’s esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy. Med Clin North Am. 2002;86:1423–1445PubMedCrossRef
8.
Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119:333–338.PubMedCrossRef
9.
Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2011;9:220–227. quiz e226.PubMedCrossRef
10.
Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the US: the importance of tumor length and lymph node status. Cancer. 2002;95:1434–1443.PubMedCrossRef
11.
Fitzgerald RC. Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut. 2006;55:1810–1820.PubMedCrossRef
12.
Shaheen NJ. Advances in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2005;128:1554–1566.PubMedCrossRef
13.
Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett’s metaplasia. Lancet. 2000;356:2079–2085.PubMedCrossRef
14.
Hutchinson L, Stenstrom B, Chen D, et al. Human Barrett’s adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. Stem Cells Dev. 2010;20:11–17.PubMedCrossRef
15.
Sarosi G, Brown G, Jaiswal K, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus. Dis Esophagus. 2008;21:43–50.PubMed
16.
Li Y, Wo JM, Ellis S, et al. Morphological transformation in esophageal submucosa by bone marrow cells: esophageal implantation under external esophageal perfusion. Stem Cells Dev. 2006;15:697–705.PubMedCrossRef
17.
Slack JM, Tosh D. Transdifferentiation and metaplasia—switching cell types. Curr Opin Genet Dev. 2001;11:581–586.PubMedCrossRef
18.
Wang J, Qin R, Ma Y, et al. Differential gene expression in normal esophagus and Barrett’s esophagus. J Gastroenterol. 2009;44:897–911.
19.
Greenawalt DM, Duong C, Smyth GK, et al. Gene expression profiling of esophageal cancer: comparative analysis of Barrett’s esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer. 2007;120:1914–1921.PubMedCrossRef
20.
Hao Y, Triadafilopoulos G, Sahbaie P, et al. Gene expression profiling reveals stromal genes expressed in common between Barrett’s esophagus and adenocarcinoma. Gastroenterology. 2006;131:925–933.PubMedCrossRef
21.
van Baal JW, Milano F, Rygiel AM, et al. A comparative analysis by SAGE of gene expression profiles of Barrett’s esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology. 2005;129:1274–1281.PubMedCrossRef
22.
Chen X, Yang CS. Barrett’s esophagus: preclinical models for investigation. In: Jobe BA, Thomas CR, Hunter JG, eds. Esophageal cancer principles and practice. New York: Demos Medical 2009:61–68.
23.
Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004;18:126–131.PubMedCrossRef
24.
Carroll DK, Carroll JS, Leong CO, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol. 2006;8:551–561.PubMedCrossRef
25.
Koster MI, Kim S, Roop DR. P63 deficiency: a failure of lineage commitment or stem cell maintenance? J Investig Dermatol Symp Proc. 2005;10:118–123.PubMedCrossRef
26.
Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol. 2001;32:1157–1165.PubMedCrossRef
27.
Daniely Y, Liao G, Dixon D, et al. Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. Am J Physiol Cell Physiol. 2004;287:C171–C181.PubMedCrossRef
28.
Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714–718.PubMedCrossRef
29.
Geddert H, Kiel S, Heep HJ, Gabbert HE, Sarbia M. The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum Pathol. 2003;34:850–856.PubMedCrossRef
30.
Roman S, Petre A, Thepot A, et al. Downregulation of p63 upon exposure to bile salts and acid in normal and cancer esophageal cells in culture. Am J Physiol Gastrointest Liver Physiol. 2007;293:G45–G53.PubMedCrossRef
31.
Chen X, Qin R, Liu B, et al. Multilayered epithelium in a rat model and human Barrett’s esophagus: Expression patterns of transcription factors and differentiation markers. BMC Gastroenterol. 2008;8:1.PubMedCrossRef
32.
Wang X, Ouyang H, Yamamoto Y, et al. Residual embryonic cells as precursors of a Barrett’s-like metaplasia. Cell. 2011;145:1023–1035.PubMedCrossRef
33.
Que J, Okubo T, Goldenring JR, et al. Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm. Development. 2007;134:2521–2531.PubMedCrossRef
34.
Offner FA, Lewin KJ, Weinstein WM. Metaplastic columnar cells in Barrett’s esophagus: a common and neglected cell type. Hum Pathol. 1996;27:885–889.PubMedCrossRef
35.
Cheng H. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. II. Mucous cells. Am J Anat. 1974;141:481–501.PubMedCrossRef
36.
Ishii Y, Rex M, Scotting PJ, Yasugi S. Region-specific expression of chicken Sox2 in the developing gut and lung epithelium: regulation by epithelial-mesenchymal interactions. Dev Dyn. 1998;213:464–475.PubMedCrossRef
37.
Kamachi Y, Uchikawa M, Kondoh H. Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet. 2000;16:182–187.PubMedCrossRef
38.
Williamson KA, Hever AM, Rainger J, et al. Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Hum Mol Genet. 2006;15:1413–1422.PubMedCrossRef
39.
Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238–1242.PubMedCrossRef
40.
Tsukamoto T, Inada K, Tanaka H, et al. Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol. 2004;130:135–145.PubMedCrossRef
41.
Tsukamoto T, Mizoshita T, Mihara M, et al. Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes. Histopathology. 2005;46:649–658.PubMedCrossRef
42.
Sherwood RI, Chen TY, Melton DA. Transcriptional dynamics of endodermal organ formation. Dev Dyn. 2009;238:29–42.PubMedCrossRef
43.
Mutoh H, Sashikawa M, Sugano K. Sox2 expression is maintained while gastric phenotype is completely lost in Cdx2-induced intestinal metaplastic mucosa. Differentiation. 2010;81:92–98.PubMedCrossRef
44.
Jonker L, Kist R, Aw A, Wappler I, Peters H. Pax9 is required for filiform papilla development and suppresses skin-specific differentiation of the mammalian tongue epithelium. Mech Dev. 2004;121:1313–1322.PubMedCrossRef
45.
Peters H, Neubuser A, Kratochwil K, Balling R. Pax9-deficient mice lack pharyngeal pouch derivatives and teeth and exhibit craniofacial and limb abnormalities. Genes Dev. 1998;12:2735–2747.PubMedCrossRef
46.
Peters H, Schuster G, Neubuser A, et al. Isolation of the Pax9 cDNA from adult human esophagus. Mamm Genome. 1997;8:62–64.PubMedCrossRef
47.
Gerber JK, Richter T, Kremmer E, et al. Progressive loss of PAX9 expression correlates with increasing malignancy of dysplastic and cancerous epithelium of the human oesophagus. J Pathol. 2002;197:293–297.PubMedCrossRef
48.
Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000;119:961–971.PubMedCrossRef
49.
Calon A, Gross I, Lhermitte B, et al. Different effects of the Cdx1 and Cdx2 homeobox genes in a murine model of intestinal inflammation. Gut. 2007;56:1688–1695.
50.
Verzi MP, Shin H, Ho LL, Liu XS, Shivdasani RA. Essential and redundant functions of Caudal family proteins in activating adult intestinal genes. Mol Cell Biol. 2011;31:1026–1039.CrossRef
51.
Kazumori H, Ishihara S, Kinoshita Y. Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barrett’s epithelium development. Gut. 2009;58:620–628.PubMedCrossRef
52.
Guo RJ, Suh ER, Lynch JP. The role of cdx proteins in intestinal development and cancer. Cancer Biol Ther. 2004;3:593–601.PubMedCrossRef
53.
Mutoh H, Hakamata Y, Sato K, et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. Biochem Biophys Res Commun. 2002;294:470–479.PubMedCrossRef
54.
Silberg DG, Sullivan J, Kang E, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology. 2002;122:689–696.PubMedCrossRef
55.
Tamai Y, Nakajima R, Ishikawa T, et al. Colonic hamartoma development by anomalous duplication in Cdx2 knockout mice. Cancer Res. 1999;59:2965–2970.PubMed
56.
Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett’s) metaplasia. Mod Pathol. 2004;17:1282–1288.PubMedCrossRef
57.
Eda A, Osawa H, Satoh K, et al. Aberrant expression of CDX2 in Barrett’s epithelium and inflammatory esophageal mucosa. J Gastroenterol. 2003;38:14–22.PubMedCrossRef
58.
Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303–310.PubMedCrossRef
59.
Phillips RW, Frierson HF Jr, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol. 2003;27:1442–1447.PubMedCrossRef
60.
Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol. 2003;16:913–919.PubMedCrossRef
61.
Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004;17:1392–1399.PubMedCrossRef
62.
Moons LM, Bax DA, Kuipers EJ, et al. The homeodomain protein CDX2 is an early marker of Barrett’s oesophagus. J Clin Pathol. 2004;57:1063–1068.PubMedCrossRef
63.
Gross I, Lhermitte B, Domon-Dell C, et al. Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation. Oncogene. 2005;24:7955–7963.
64.
Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y. MiR-9 down-regulates CDX2 expression in gastric cancer cells. Int J Cancer. 2011;129:2611–2620. PubMedCrossRef
65.
Park J, Schulz S, Waldman SA. Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2. Gastroenterology. 2000;119:89–96.PubMedCrossRef
66.
Boudreau F, Rings EH, van Wering HM, et al. Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene. J Biol Chem. 2002;277:31909–31917.PubMedCrossRef
67.
Braunstein EM, Qiao XT, Madison B, et al. Villin: A marker for development of the epithelial pyloric border. Dev Dyn. 2002;224:90–102.PubMedCrossRef
68.
Mesquita P, Jonckheere N, Almeida R, et al. Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines. J Biol Chem. 2003;278:51549–51556.PubMedCrossRef
69.
Shimada T, Koike T, Yamagata M, Yoneda M, Hiraishi H. Regulation of TFF3 expression by homeodomain protein CDX2. Regul Pept. 2007;140:81–87.PubMedCrossRef
70.
Liu T, Zhang X, So CK, et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis. 2007;28:488–496.PubMedCrossRef
71.
Mutoh H, Sakamoto H, Hayakawa H, et al. The intestine-specific homeobox gene Cdx2 induces expression of the basic helix-loop-helix transcription factor Math1. Differentiation. 2006;74:313–321.PubMedCrossRef
72.
Boyd M, Hansen M, Jensen TG, et al. Genome-wide analysis of CDX2 binding in intestinal epithelial cells (Caco-2). J Biol Chem. 2010;285:25115–25125.PubMedCrossRef
73.
Uesaka T, Kageyama N, Watanabe H. Identifying target genes regulated downstream of Cdx2 by microarray analysis. J Mol Biol. 2004;337:647–660.PubMedCrossRef
74.
Jensen J, Pedersen EE, Galante P, et al. Control of endodermal endocrine development by Hes-1. Nat Genet. 2000;24:36–44.PubMedCrossRef
75.
Yang Q, Bermingham NA, Finegold MJ, Zoghbi HY. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science. 2001;294:2155–2158.PubMedCrossRef
76.
Marchetti M, Caliot E, Pringault E. Chronic acid exposure leads to activation of the cdx2 intestinal homeobox gene in a long-term culture of mouse esophageal keratinocytes. J Cell Sci. 2003;116:1429–1436.PubMedCrossRef
77.
Kazumori H, Ishihara S, Rumi MA, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett’s epithelium. Gut. 2006;55:16–25.PubMedCrossRef
78.
Kong J, Crissey MA, Funakoshi S, Kreindler JL, Lynch JP. Ectopic Cdx2 expression in murine esophagus models: an intermediate stage in the emergence of Barrett’s esophagus. PLoS ONE. 2011;6:e18280.PubMedCrossRef
79.
Silberg DG, Furth EE, Taylor JK, et al. CDX1 protein expression in normal, metaplastic, and neoplastic human alimentary tract epithelium. Gastroenterology. 1997;113:478–486.PubMedCrossRef
80.
Wong NA, Wilding J, Bartlett S, et al. CDX1 is an important molecular mediator of Barrett’s metaplasia. Proc Natl Acad Sci USA. 2005;102:7565–7570.PubMedCrossRef
81.
Eda A, Osawa H, Yanaka I, et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol. 2002;37:94–100.PubMedCrossRef
82.
Mutoh H, Sakurai S, Satoh K, et al. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut. 2004;53:1416–1423.PubMedCrossRef
83.
Yu WY, Slack JM, Tosh D. Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. Dev Biol. 2005;284:157–170.PubMedCrossRef
84.
Rozek LS, Lipkin SM, Fearon ER, et al. CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Res. 2005;65:5488–5492.PubMedCrossRef
85.
Sivagnanasundaram S, Islam I, Talbot I, et al. The homeobox gene CDX2 in colorectal carcinoma: a genetic analysis. Br J Cancer. 2001;84:218–225.PubMedCrossRef
86.
Hinoi T, Loda M, Fearon ER. Silencing of CDX2 expression in colon cancer via a dominant repression pathway. J Biol Chem. 2003;278:44608–44616.PubMedCrossRef
87.
Wong NA, Britton MP, Choi GS, et al. Loss of CDX1 expression in colorectal carcinoma: promoter methylation, mutation, and loss of heterozygosity analyses of 37 cell lines. Proc Natl Acad Sci USA. 2004;101:574–579.PubMedCrossRef
88.
Lickert H, Kemler R. Functional analysis of cis-regulatory elements controlling initiation and maintenance of early Cdx1 gene expression in the mouse. Dev Dyn. 2002;225:216–220.PubMedCrossRef
89.
Rankin EB, Xu W, Silberg DG, Suh E. Putative intestine-specific enhancers located in 5′ sequence of the CDX1 gene regulate CDX1 expression in the intestine. Am J Physiol Gastrointest Liver Physiol. 2004;286:G872–G880.PubMedCrossRef
90.
Huo X, Zhang HY, Zhang XI, et al. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett’s esophagus. Gastroenterology. 2010;139:194–203. e191.PubMedCrossRef
91.
Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol. 2004;199:354–363.PubMedCrossRef
92.
Odom DT, Zizlsperger N, Gordon DB, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science.. 2004;303:1378–1381.PubMedCrossRef
93.
Watt AJ, Garrison WD, Duncan SA. HNF4: a central regulator of hepatocyte differentiation and function. Hepatology. 2003;37:1249–1253.PubMedCrossRef
94.
D’Angelo A, Bluteau O, Garcia-Gonzalez MA, et al. Hepatocyte nuclear factor 1alpha and beta control terminal differentiation and cell fate commitment in the gut epithelium. Development. 2010;137:1573–1582.PubMedCrossRef
95.
Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1alpha and the caudal-related homeodomain protein 2. Mol Pharmacol. 2004;65:953–963.PubMedCrossRef
96.
Benoit YD, Pare F, Francoeur C, et al. Cooperation between HNF-1alpha, Cdx2, and GATA-4 in initiating an enterocytic differentiation program in a normal human intestinal epithelial progenitor cell line. Am J Physiol Gastrointest Liver Physiol. 2010;298:G504–G517.PubMedCrossRef
97.
Piessen G, Jonckheere N, Vincent A, et al. Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha. Biochem J. 2007;402:81–91.PubMedCrossRef
98.
Divine JK, McCaul SP, Simon TC. HNF-1alpha and endodermal transcription factors cooperatively activate Fabpl: MODY3 mutations abrogate cooperativity. Am J Physiol Gastrointest Liver Physiol. 2003;285:G62–G72.PubMed
99.
Divine JK, Staloch LJ, Haveri H, et al. GATA-4, GATA-5, and GATA-6 activate the rat liver fatty acid binding protein gene in concert with HNF-1alpha. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1086–G1099.PubMedCrossRef
100.
Bosse T, Fialkovich JJ, Piaseckyj CM, et al. Gata4 and Hnf1alpha are partially required for the expression of specific intestinal genes during development. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1302–G1314.PubMedCrossRef
101.
Bosse T, van Wering HM, Gielen M, et al. Hepatocyte nuclear factor-1alpha is required for expression but dispensable for histone acetylation of the lactase-phlorizin hydrolase gene in vivo. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1016–G1024.PubMedCrossRef
102.
Lin L, Miller CT, Contreras JI, et al. The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res. 2002;62:5273–5279.PubMed
103.
Crisera CA, Connelly PR, Marmureanu AR, et al. TTF-1 and HNF-3beta in the developing tracheoesophageal fistula: further evidence for the respiratory origin of the distal esophagus’. J Pediatr Surg. 1999;34:1322–1326.PubMedCrossRef
104.
Wan H, Kaestner KH, Ang SL, et al. Foxa2 regulates alveolarization and goblet cell hyperplasia. Development. 2004;131:953–964.PubMedCrossRef
105.
Zheng W, Rosenstiel P, Huse K, et al. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun. 2006;7:11–18.PubMedCrossRef
106.
van der Sluis M, Vincent A, Bouma J, et al. Forkhead box transcription factors Foxa1 and Foxa2 are important regulators of Muc2 mucin expression in intestinal epithelial cells. Biochem Biophys Res Commun. 2008;369:1108–1113.PubMedCrossRef
107.
Ye DZ, Kaestner KH. Foxa1 and Foxa2 control the differentiation of goblet and enteroendocrine L- and D-cells in mice. Gastroenterology. 2009;137:2052–2062.PubMedCrossRef
108.
Cattin AL, Le Beyec J, Barreau F, et al. Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium. Mol Cell Biol. 2009;29:6294–6308.PubMedCrossRef
109.
Garrison WD, Battle MA, Yang C, et al. Hepatocyte nuclear factor 4alpha is essential for embryonic development of the mouse colon. Gastroenterology. 2006;130:1207–1220.PubMedCrossRef
110.
Babeu JP, Darsigny M, Lussier CR, Boudreau F. Hepatocyte nuclear factor 4alpha contributes to an intestinal epithelial phenotype in vitro and plays a partial role in mouse intestinal epithelium differentiation. Am J Physiol Gastrointest Liver Physiol. 2009;297:G124–G134.PubMedCrossRef
111.
Hatzis P, Talianidis I. Regulatory mechanisms controlling human hepatocyte nuclear factor 4alpha gene expression. Mol Cell Biol. 2001;21:7320–7330.PubMedCrossRef
112.
Nastos A, Pogge von Strandmann E, Weber H, Ryffel GU. The embryonic expression of the tissue-specific transcription factor HNF1alpha in Xenopus: rapid activation by HNF4 and delayed induction by mesoderm inducers. Nucleic Acids Res. 1998;26:5602–5608.PubMedCrossRef
113.
Weber H, Holewa B, Jones EA, Ryffel GU. Mesoderm and endoderm differentiation in animal cap explants: identification of the HNF4-binding site as an activin A responsive element in the Xenopus HNF1alpha promoter. Development. 1996;122:1975–1984.PubMed
114.
Molkentin JD. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem. 2000;275:38949–38952.PubMedCrossRef
115.
Jacobsen CM, Narita N, Bielinska M, et al. Genetic mosaic analysis reveals that GATA-4 is required for proper differentiation of mouse gastric epithelium. Dev Biol. 2002;241:34–46.PubMedCrossRef
116.
Zhang Y, Rath N, Hannenhalli S, et al. GATA and Nkx factors synergistically regulate tissue-specific gene expression and development in vivo. Development. 2007;134:189–198.PubMedCrossRef
117.
Al-azzeh ED, Fegert P, Blin N, Gott P. Transcription factor GATA-6 activates expression of gastroprotective trefoil genes TFF1 and TFF2. Biochim Biophys Acta. 2000;1490:324–332.PubMed
118.
van Wering HM, Bosse T, Musters A, et al. Complex regulation of the lactase-phlorizin hydrolase promoter by GATA-4. Am J Physiol Gastrointest Liver Physiol. 2004;287:G899–G909.PubMedCrossRef
119.
Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm differentiation. Development. 1998;125:4909–4917.PubMed
120.
Gao X, Sedgwick T, Shi YB, Evans T. Distinct functions are implicated for the GATA-4, -5, and -6 transcription factors in the regulation of intestine epithelial cell differentiation. Mol Cell Biol. 1998;18:2901–2911.PubMed
121.
Sumi K, Tanaka T, Uchida A, et al. Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. Mol Cell Biol. 2007;27:4248–4260.PubMedCrossRef
122.
Afouda BA, Ciau-Uitz A, Patient R. GATA4, 5 and 6 mediate TGF{beta} maintenance of endodermal gene expression in Xenopus embryos. Development. 2005;132:763–774.PubMedCrossRef
123.
Morrisey EE, Tang Z, Sigrist K, et al. GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo. Genes Dev. 1998;12:3579–3590.PubMedCrossRef
124.
Belaguli NS, Zhang M, Rigi M, Aftab M, Berger DH. Cooperation between GATA4 and TGF-beta signaling regulates intestinal epithelial gene expression. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1520–G1533.PubMedCrossRef
125.
Nemer G, Nemer M. Transcriptional activation of BMP-4 and regulation of mammalian organogenesis by GATA-4 and -6. Dev Biol. 2003;254:131–148.PubMedCrossRef
126.
Haveri H, Westerholm-Ormio M, Lindfors K, et al. Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterol. 2008;8:9.PubMedCrossRef
127.
Miller CT, Moy JR, Lin L, et al. Gene amplification in esophageal adenocarcinomas and Barrett’s with high-grade dysplasia. Clin Cancer Res. 2003;9:4819–4825.PubMed
128.
Guo M, House MG, Akiyama Y, et al. Hypermethylation of the GATA gene family in esophageal cancer. Int J Cancer. 2006;119:2078–2083.PubMedCrossRef
129.
Alvarez H, Opalinska J, Zhou L, et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet. 2011;7:e1001356.PubMedCrossRef
130.
Krishnadath KK. Novel findings in the pathogenesis of esophageal columnar metaplasia or Barrett’s esophagus. Curr Opin Gastroenterol. 2007;23:440–445.PubMedCrossRef
131.
Milano F, van Baal JW, Buttar NS, et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology. 2007;132:2412–2421.PubMedCrossRef
132.
Domyan ET, Ferretti E, Throckmorton K, et al. Signaling through BMP receptors promotes respiratory identity in the foregut via repression of Sox2. Development. 2011;138:971–981.PubMedCrossRef
133.
Rodriguez P, Da Silva S, Oxburgh L, et al. BMP signaling in the development of the mouse esophagus and forestomach. Development. 2010;137:4171–4176.PubMedCrossRef
134.
Auclair BA, Benoit YD, Rivard N, Mishina Y, Perreault N. Bone morphogenetic protein signaling is essential for terminal differentiation of the intestinal secretory cell lineage. Gastroenterology. 2007;133:887–896.PubMedCrossRef
135.
Que J, Choi M, Ziel JW, Klingensmith J, Hogan BL. Morphogenesis of the trachea and esophagus: current players and new roles for noggin and Bmps. Differentiation. 2006;74:422–437.PubMedCrossRef
136.
Batts LE, Polk DB, Dubois RN, Kulessa H. Bmp signaling is required for intestinal growth and morphogenesis. Dev Dyn. 2006;235:1563–1570.PubMedCrossRef
137.
Onwuegbusi BA, Aitchison A, Chin SF, et al. Impaired transforming growth factor beta signalling in Barrett’s carcinogenesis due to frequent SMAD4 inactivation. Gut. 2006;55:764–774.PubMedCrossRef
138.
Onwuegbusi BA, Rees JR, Lao-Sirieix P, Fitzgerald RC. Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines. PLoS ONE. 2007;2:e177.PubMedCrossRef
139.
Calon A, Gross I, Davidson I, et al. Functional interaction between the homeoprotein CDX1 and the transcriptional machinery containing the TATA-binding protein. Nucleic Acids Res. 2007;35:175–185.PubMedCrossRef
140.
Gregorieff A, Pinto D, Begthel H, et al. Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology. 2005;129:626–638.PubMed
141.
van Es JH, Jay P, Gregorieff A, et al. Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat Cell Biol. 2005;7:381–386.PubMedCrossRef
142.
Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 2005;19:877–890.PubMedCrossRef
143.
Clement G, Jablons DM, Benhattar J. Targeting the Wnt signaling pathway to treat Barrett’s esophagus. Expert Opin Ther Targets. 2007;11:375–389.PubMedCrossRef
144.
Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett’s esophagus. Oncogene. 2006;25:3084–3092.PubMedCrossRef
145.
Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett’s esophagus and associated adenocarcinoma. Cancer Res. 2000;60:5021–5026.PubMed
146.
Bailey T, Biddlestone L, Shepherd N, et al. Altered cadherin and catenin complexes in the Barrett’s esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol. 1998;152:135–144.PubMed
147.
Lickert H, Domon C, Huls G, et al. Wnt/(beta)-catenin signaling regulates the expression of the homeobox gene Cdx1 in embryonic intestine. Development. 2000;127:3805–3813.PubMed
148.
Pilon N, Oh K, Sylvestre JR, Savory JG, Lohnes D. Wnt signaling is a key mediator of Cdx1 expression in vivo. Development. 2007;134:2315–2323.PubMedCrossRef
149.
Murata-Kamiya N, Kurashima Y, Teishikata Y, et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 2007;26:4617–4626.PubMedCrossRef
150.
Saegusa M, Hashimura M, Kuwata T, et al. A functional role of Cdx2 in {beta}-catenin signaling during transdifferentiation in endometrial carcinomas. Carcinogenesis. 2007;28:1885–1892.PubMedCrossRef
151.
Okubo A, Miyoshi O, Baba K, et al. A novel GATA4 mutation completely segregated with atrial septal defect in a large Japanese family. J Med Genet. 2004;41:e97.PubMedCrossRef
152.
Bastide P, Darido C, Pannequin J, et al. Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J Cell Biol. 2007;178:635–648.PubMedCrossRef
153.
Blache P, van de Wetering M, Duluc I, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol. 2004;166:37–47.PubMedCrossRef
154.
Topol L, Chen W, Song H, Day TF, Yang Y. Sox9 inhibits Wnt signaling by promoting beta-catenin phosphorylation in the nucleus. J Biol Chem. 2009;284:3323–3333.PubMedCrossRef
155.
Mori-Akiyama Y, van den Born M, van Es JH, et al. SOX9 is required for the differentiation of paneth cells in the intestinal epithelium. Gastroenterology. 2007;133:539–546.PubMedCrossRef
156.
Sumi E, Iehara N, Akiyama H, et al. SRY-related HMG box 9 regulates the expression of Col4a2 through transactivating its enhancer element in mesangial cells. Am J Pathol. 2007;170:1854–1864.PubMedCrossRef
157.
Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem. 2000;275:3687–3692.PubMedCrossRef
158.
Manuylov NL, Fujiwara Y, Adameyko II, Poulat F, Tevosian SG. The regulation of Sox9 gene expression by the GATA4/FOG2 transcriptional complex in dominant XX sex reversal mouse models. Dev Biol. 2007;307:356–367.PubMedCrossRef
159.
Wang DH, Clemons NJ, Miyashita T, et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett’s metaplasia. Gastroenterology. 2010;138:1810–1822.PubMedCrossRef
160.
Chen G, Korfhagen TR, Xu Y, et al. SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production. J Clin Invest. 2009;119:2914–2924.PubMedCrossRef
161.
Park KS, Korfhagen TR, Bruno MD, et al. SPDEF regulates goblet cell hyperplasia in the airway epithelium. J Clin Invest. 2007;117:978–988.PubMedCrossRef
162.
Gregorieff A, Stange DE, Kujala P, et al. The ets-domain transcription factor Spdef promotes maturation of goblet and paneth cells in the intestinal epithelium. Gastroenterology. 2009;137:1333–1345. e1331-1333.PubMedCrossRef
163.
O’Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100:1257–1264.PubMedCrossRef
164.
Si J, Fu X, Behar J, et al. NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett’s esophageal adenocarcinoma cells. J Biol Chem. 2007;282:16244–16255.PubMedCrossRef
165.
Konturek PC, Nikiforuk A, Kania J, et al. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett’s esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci. 2004;49:1075–1083.PubMedCrossRef
166.
Jenkins GJ, Harries K, Doak SH, et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis. 2004;25:317–323.PubMedCrossRef
167.
Debruyne PR, Witek M, Gong L, et al. Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells. Gastroenterology. 2006;130:1191–1206.PubMedCrossRef
168.
Ikeda H, Sasaki M, Ishikawa A, et al. Interaction of Toll-like receptors with bacterial components induces expression of CDX2 and MUC2 in rat biliary epithelium in vivo and in culture. Lab Invest. 2007;87:559–571.PubMed
169.
Wallace KN, Pack M. Unique and conserved aspects of gut development in zebrafish. Dev Biol. 2003;255:12–29.PubMedCrossRef
170.
Litingtung Y, Lei L, Westphal H, Chiang C. Sonic hedgehog is essential to foregut development. Nat Genet. 1998;20:58–61.PubMedCrossRef
171.
Xie K, Abbruzzese JL. Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers. Cancer Cell. 2003;4:245–247.PubMedCrossRef
172.
Watkins DN, Peacock CD. Hedgehog signalling in foregut malignancy. Biochem Pharmacol. 2004;68:1055–1060.PubMedCrossRef
173.
Yamanaka Y, Shiotani A, Fujimura Y, et al. Expression of Sonic hedgehog (SHH) and CDX2 in the columnar epithelium of the lower oesophagus. Dig Liver Dis. 2011;43:54–59.PubMedCrossRef
174.
van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959–963.PubMedCrossRef
175.
Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411, 575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876–12882.PubMedCrossRef
176.
Milano J, McKay J, Dagenais C, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82:341–358.PubMedCrossRef
177.
Kazanjian A, Noah T, Brown D, Burkart J, Shroyer NF. Atonal homolog 1 is required for growth and differentiation effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal epithelial cells. Gastroenterology. 2010;139:918–928. 928 e911-916.PubMedCrossRef
178.
Stanger BZ, Datar R, Murtaugh LC, Melton DA. Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci USA. 2005;102:12443–12448.PubMedCrossRef
179.
Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, et al. NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology. 2010;139:2113–2123.PubMedCrossRef
180.
Nguyen BC, Lefort K, Mandinova A, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 2006;20:1028–1042.PubMedCrossRef
181.
Morrow DJ, Avissar NE, Toia L, et al. Pathogenesis of Barrett’s esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells. Surgery. 2009;146:714–721. discussion 721–712.PubMedCrossRef
182.
Menke V, van Es JH, de Lau W, et al. Conversion of metaplastic Barrett’s epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis Model Mech. 2010;3:104–110.PubMedCrossRef
183.
Lao-Sirieix P, Fitzgerald RC. Role of the micro-environment in Barrett’s carcinogenesis. Biochem Soc Trans. 2010;38:327–330.PubMedCrossRef
184.
Harrison RF, Perry I, Jankowski JA. Barrett’s mucosa: remodelling by the microenvironment. J Pathol. 2000;192:1–3.PubMedCrossRef
185.
Saadi A, Shannon NB, Lao-Sirieix P, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA. 2010;107:2177–2182.PubMedCrossRef
186.
Colleypriest BJ, Ward SG, Tosh D. How does inflammation cause Barrett’s metaplasia? Curr Opin Pharmacol. 2009;9:721–726.PubMedCrossRef
187.
Stairs DB, Kong J, Lynch JP. Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia. Prog Mol Biol Transl Sci. 2010;96:231–270.PubMedCrossRef
188.
Moons LM, Kusters JG, van Delft JH, et al. A pro-inflammatory genotype predisposes to Barrett’s esophagus. Carcinogenesis. 2008;29:926–931.PubMedCrossRef
189.
Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett’s oesophagus: implications for disease complications. Gut. 2002;51:316–322.PubMedCrossRef
190.
Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137:1776–1784.PubMedCrossRef
191.
Quante M, Abrams JA, Marrache F, Wang TC (2010). Barrett’s esophagus correlates with increased putative gastrointestinal stem cell markers DCLK1 and CCK2R in a IL1b mouse model and in humans. In DDW.
192.
Seery JP, Watt FM. Asymmetric stem-cell divisions define the architecture of human oesophageal epithelium. Curr Biol. 2000;10:1447–1450.PubMedCrossRef
193.
Takito J, Al-Awqati Q. Conversion of ES cells to columnar epithelia by hensin and to squamous epithelia by laminin. J Cell Biol. 2004;166:1093–1102.PubMedCrossRef
194.
Benahmed F, Gross I, Guenot D, et al. The microenvironment controls CDX2 homeobox gene expression in colorectal cancer cells. Am J Pathol. 2007;170:733–744.PubMedCrossRef
195.
Lorentz O, Duluc I, Arcangelis AD, et al. Key role of the Cdx2 homeobox gene in extracellular matrix-mediated intestinal cell differentiation. J Cell Biol. 1997;139:1553–1565.PubMedCrossRef
196.
Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in human Barrett’s carcinogenesis. Int J Cancer. 2010;129:1661–1670.
197.
Nguyen GH, Schetter AJ, Chou DB, et al. Inflammatory and microRNA gene expression as prognostic classifier of Barrett’s-associated esophageal adenocarcinoma. Clin Cancer Res. 2010;16:5824–5834.PubMedCrossRef
198.
Wijnhoven BP, Hussey DJ, Watson DI, et al. MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010;97:853–861.PubMedCrossRef
199.
Yang H, Gu J, Wang KK, et al. MicroRNA expression signatures in Barrett’s esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15:5744–5752.PubMedCrossRef
200.
Maru DM, Singh RR, Hannah C, et al. MicroRNA-196a is a potential marker of progression during Barrett’s metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009;174:1940–1948.PubMedCrossRef
201.
Dijckmeester WA, Wijnhoven BP, Watson DI, et al. MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett’s esophagus. J Gastrointest Surg. 2009;13:846–853.PubMedCrossRef
202.
Bansal A, Lee IH, Hong X, et al. Feasibility of microRNAs as biomarkers for Barrett’s esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol. 2011;106:1055–1063.PubMedCrossRef
203.
Smith CM, Watson DI, Michael MZ, Hussey DJ. MicroRNAs, development of Barrett’s esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol. 2010;16:531–537.PubMedCrossRef
204.
Kan T, Meltzer SJ. MicroRNAs in Barrett’s esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol. 2009;9:727–732.PubMedCrossRef
205.
Boominathan L. The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS ONE. 2010;5:e10615.PubMedCrossRef
206.
207.
Gudas LJ, Wagner JA. Retinoids regulate stem cell differentiation. J Cell Physiol. 2011;226:322–330.PubMedCrossRef
208.
Prinos P, Joseph S, Oh K, et al. Multiple pathways governing Cdx1 expression during murine development. Dev Biol. 2001;239:257–269.PubMedCrossRef
209.
Houle M, Sylvestre JR, Lohnes D. Retinoic acid regulates a subset of Cdx1 function in vivo. Development. 2003;130:6555–6567.PubMedCrossRef
210.
Qian A, Cai Y, Magee TR, Wan YJ. Identification of retinoic acid-responsive elements on the HNF1alpha and HNF4alpha genes. Biochem Biophys Res Commun. 2000;276:837–842.PubMedCrossRef
211.
Arceci RJ, King AA, Simon MC, Orkin SH, Wilson DB. Mouse GATA-4: a retinoic acid-inducible GATA-binding transcription factor expressed in endodermally derived tissues and heart. Mol Cell Biol. 1993;13:2235–2246.PubMed
212.
Afonja O, Raaka BM, Huang A, et al. RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene. 2002;21:7850–7860.PubMedCrossRef
213.
Chang CL, Hong E, Lao-Sirieix P, Fitzgerald RC. A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett’s associated adenocarcinoma. Oncogene. 2008;27:2951–2960.PubMedCrossRef
214.
Hormi-Carver K, Feagins LA, Spechler SJ, Souza RF. All trans-retinoic acid induces apoptosis via p38 and caspase pathways in metaplastic Barrett’s cells. Am J Physiol Gastrointest Liver Physiol. 2007;292:G18–G27.PubMedCrossRef
215.
Lord RV, Tsai PI, Danenberg KD, et al. Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett’s intestinal metaplasia, dysplasia, adenocarcinoma sequence. Surgery. 2001;129:267–276.PubMedCrossRef
216.
Brabender J, Lord RV, Metzger R, et al. Role of retinoid X receptor mRNA expression in Barrett’s esophagus. J Gastrointest Surg. 2004;8:413–422.PubMedCrossRef
217.
Chang CL, Lao-Sirieix P, Save V, et al. Retinoic acid-induced glandular differentiation of the oesophagus. Gut. 2007;56:906–917.PubMedCrossRef
218.
Cooke G, Blanco-Fernandez A, Seery JP. The effect of retinoic acid and deoxycholic acid on the differentiation of primary human esophageal keratinocytes. Dig Dis Sci. 2008;53:2851–2857.PubMedCrossRef
219.
Hiramatsu T, Osaki M, Ito Y, et al. Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology. 2005;72:316–324.PubMedCrossRef
220.
Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene. 2005;24:4138–4148.PubMed
221.
Smith E, De Young NJ, Pavey SJ, et al. Similarity of aberrant DNA methylation in Barrett’s esophagus and esophageal adenocarcinoma. Mol Cancer. 2008;7:75.PubMedCrossRef
222.
Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009;69:4112–4115.PubMedCrossRef
223.
Fukamachi H. Runx3 controls growth and differentiation of gastric epithelial cells in mammals. Dev Growth Differ. 2006;48:1–13.PubMedCrossRef
224.
Torquati A, O’Rear L, Longobardi L, et al. RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery. 2004;136:310–316.PubMedCrossRef
225.
Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell. 2008;14:226–237.PubMedCrossRef
226.
Ito K, Liu Q, Salto-Tellez M, et al. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res. 2005;65:7743–7750.PubMedCrossRef
227.
Guo WH, Weng LQ, Ito K, et al. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. Oncogene.. 2002;21:8351–8355.PubMedCrossRef
228.
Fukamachi H, Mimata A, Tanaka I, et al. In vitro differentiation of Runx3−/− p53−/− gastric epithelial cells into intestinal type cells. Cancer Sci 2008;99:671–676.PubMedCrossRef
229.
Fukamachi H, Ito K, Ito Y. Runx3−/− gastric epithelial cells differentiate into intestinal type cells. Biochem Biophys Res Commun. 2004;321:58–64.PubMedCrossRef
230.
Katz JP, Perreault N, Goldstein BG, et al. The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development. 2002;129:2619–2628.PubMed
231.
Flandez M, Guilmeau S, Blache P, Augenlicht LH. KLF4 regulation in intestinal epithelial cell maturation. Exp Cell Res. 2008;314:3712–3723.PubMedCrossRef
232.
Ghaleb AM, Aggarwal G, Bialkowska AB, Nandan MO, Yang VW. Notch inhibits expression of the Kruppel-like factor 4 tumor suppressor in the intestinal epithelium. Mol Cancer Res. 2008;6:1920–1927.PubMedCrossRef
233.
Zheng H, Pritchard DM, Yang X, et al. KLF4 gene expression is inhibited by the notch signaling pathway that controls goblet cell differentiation in mouse gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2009;296:G490–G498.PubMedCrossRef
234.
Hu D, Wan Y. Regulation of Kruppel-like factor 4 by the anaphase promoting complex pathway is involved in TGF-beta signaling. J Biol Chem. 2011;286:6890–6901.PubMedCrossRef
235.
Tetreault MP, Yang Y, Travis J, et al. Esophageal squamous cell dysplasia and delayed differentiation with deletion of kruppel-like factor 4 in murine esophagus. Gastroenterology. 2010;139:171–181. e179.PubMedCrossRef
236.
Goldstein BG, Chao HH, Yang Y, et al. Overexpression of Kruppel-like factor 5 in esophageal epithelia in vivo leads to increased proliferation in basal but not suprabasal cells. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1784–G1792.PubMedCrossRef
237.
Kazumori H, Ishihara S, Takahashi Y, Amano Y, Kinoshita Y. Roles of Kruppel-like factor 4 in oesophageal epithelial cells in Barrett’s epithelium development. Gut. 2011;60:608–617.PubMedCrossRef
238.
McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther. 2011;34:146–165.PubMedCrossRef
239.
Souza RF. The role of acid and bile reflux in oesophagitis and Barrett’s metaplasia. Biochem Soc Trans. 2010;38:348–352.PubMedCrossRef
240.
Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia. Am J Physiol Gastrointest Liver Physiol. 2008;295:G211–G218.PubMedCrossRef
241.
Fitzgerald RC. Barrett’s oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut. 2005;54:i21–i26.PubMedCrossRef
242.
Wang DH, Souza RF. Biology of Barrett’s esophagus and esophageal adenocarcinoma. Gastrointest Endosc Clin N Am. 2011;21:25–38.PubMedCrossRef
243.
Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett. 2009;275:170–177.PubMedCrossRef
244.
Ong CA, Lao-Sirieix P, Fitzgerald RC. Biomarkers in Barrett’s esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol. 2010;16:5669–5681.PubMedCrossRef
245.
Grotenhuis BA, van Lanschot JJ, Dinjens WN, Wijnhoven BP. The pathogenesis of Barrett’s metaplasia and the progression to esophageal adenocarcinoma. Recent Results Cancer Res. 2010;182:39–63.PubMedCrossRef
Metadaten
Titel
Molecular Mechanisms of Barrett’s Esophagus
verfasst von
Hao Chen
Yu Fang
Whitney Tevebaugh
Roy C. Orlando
Nicholas J. Shaheen
Xiaoxin Chen
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1885-6

Weitere Artikel der Ausgabe 12/2011

Digestive Diseases and Sciences 12/2011 Zur Ausgabe

Original Article

Montelukast Was Inefficient in Maintaining Steroid-Induced Remission in Adult Eosinophilic Esophagitis

Original Article

Serum sTREM-1 as a Surrogate Marker of Treatment Outcome in Patients with Peptic Ulcer Disease

Original Article

Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database

Original Article

Self-Expanding Metal Stents for Biliary Drainage in Patients with Resectable Pancreatic Cancer: Single-Center Experience with 79 Cases

Original Article

Th1 Responses Are More Susceptible to Infliximab-Mediated Immunosuppression Than Th17 Responses

Original Article

Cross-Sectional Imaging Obtained Immediately Following Radiofrequency Atrial Fibrillation Ablation Does Not Predict Endoscopic Evidence of Esophageal Injury

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise